ZIVO ZIVO BIOSCIENCE INC COM NEW revenue, earnings and financials
For the quarter ended September 30, 2025, ZIVO BIOSCIENCE INC COM NEW reported revenue of $65.6K (up 108.3% from a year earlier), net income of −$1.03M and diluted EPS of −$0.27; over the last four quarters revenue was $209K and net income −$8.49M; for the fiscal year ended December 2024 revenue was $157K, up 468.6% on the year before.
ZIVO annual revenue and earnings
- Fiscal year ended Dec 2024: revenue $157K, gross profit $49.0K, operating income −$13.4M, net income −$13.4M (margin -8513.4%), EPS −$4.23
- Fiscal year ended Dec 2023: revenue $27.7K, gross profit $11.6K, operating income −$7.26M, net income −$7.78M (margin -28127.2%), EPS −$4.60
- Fiscal year ended Dec 2022: revenue $0, gross profit $0, operating income −$8.73M, net income −$8.75M (margin n/a), EPS n/a
- Fiscal year ended Dec 2021: revenue $0, gross profit n/a, operating income −$8.65M, net income −$8.76M (margin n/a), EPS n/a
ZIVO quarterly revenue and earnings
- Quarter ended Sep 30, 2025: revenue $65.6K (up 108.3% year over year), net income −$1.03M, EPS −$0.27
- Quarter ended Jun 30, 2025: revenue $53.4K, net income −$1.64M, EPS −$0.43
- Quarter ended Mar 31, 2025: revenue $0 (down 100.0% year over year), net income −$4.21M, EPS −$1.12
- Quarter ended Dec 31, 2024 (from the annual report): revenue $90.0K (up 662.7% year over year), net income −$1.60M, EPS −$0.31
- Quarter ended Sep 30, 2024: revenue $31.5K (up 166.9% year over year), net income −$2.27M, EPS −$0.67
- Quarter ended Jun 30, 2024: revenue $0 (down 100.0% year over year), net income −$8.24M, EPS −$2.78
- Quarter ended Mar 31, 2024: revenue $35.7K, net income −$1.28M, EPS −$0.47
- Quarter ended Dec 31, 2023 (from the annual report): revenue $11.8K, net income −$1.91M, EPS n/a
- Quarter ended Sep 30, 2023: revenue $11.8K, net income −$1.82M, EPS n/a
- Quarter ended Jun 30, 2023: revenue $4.05K, net income −$2.07M, EPS n/a
- Quarter ended Mar 31, 2023: revenue $0, net income −$1.97M, EPS n/a
- Quarter ended Dec 31, 2022 (from the annual report): revenue $0, net income −$2.64M, EPS n/a
- Quarter ended Sep 30, 2022: revenue $0, net income −$2.00M, EPS n/a
- Quarter ended Jun 30, 2022: revenue $0, net income −$2.07M, EPS n/a
- Quarter ended Mar 31, 2022: revenue $0, net income −$2.03M, EPS n/a
- Quarter ended Dec 31, 2021 (from the annual report): revenue $0, net income −$3.14M, EPS n/a
- Quarter ended Sep 30, 2021: revenue $0, net income −$1.55M, EPS −$0.21
- Quarter ended Jun 30, 2021: revenue $0, net income −$1.85M, EPS −$0.28
- Quarter ended Mar 31, 2021: revenue $0, net income −$2.22M, EPS −$0.01
ZIVO cash flow, buybacks and dividends
- Fiscal year ended Dec 2024: operating cash flow −$4.31M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$5.80M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$7.10M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$6.80M, share buybacks n/a
ZIVO balance sheet
- Sep 30, 2025: cash n/a, total assets $559K, total liabilities $3.85M, shareholders' equity −$3.29M
- Jun 30, 2025: cash n/a, total assets $703K, total liabilities $3.24M, shareholders' equity −$2.54M
- Mar 31, 2025: cash n/a, total assets $1.33M, total liabilities $2.95M, shareholders' equity −$1.62M
- Dec 31, 2024: cash n/a, total assets $1.64M, total liabilities $2.16M, shareholders' equity −$515K
- Sep 30, 2024: cash n/a, total assets $496K, total liabilities $2.58M, shareholders' equity −$2.08M
- Jun 30, 2024: cash n/a, total assets $576K, total liabilities $2.87M, shareholders' equity −$2.30M
- Mar 31, 2024: cash n/a, total assets $816K, total liabilities $3.09M, shareholders' equity −$2.27M
- Dec 31, 2023: cash n/a, total assets $556K, total liabilities $2.76M, shareholders' equity −$2.21M
What is ZIVO's revenue?
ZIVO BIOSCIENCE INC COM NEW reported $209K of revenue over its last four quarters, through September 30, 2025.
Is ZIVO profitable?
No. ZIVO BIOSCIENCE INC COM NEW lost $8.49M over the last four quarters.
What is ZIVO's EPS?
Diluted earnings per share over the last four quarters were −$2.13; −$0.27 in the latest quarter.